Psilocybin for Depression and Anxiety in Cancer Patients
2025 Tammie E. Quest, Ali John Zarrabi
Abstract Fifty-one cancer patients with symptoms of depression and anxiety were enrolled in a randomized, double-blind, crossover trial using low-dose psilocybin (placebo) and high-dose psilocybin (intervention group) combined with psychotherapy with 5 weeks between dosing sessions and at 6-month follow-up. Participants in the intervention group had large decreases in clinician- and self-rated...
DOI: 10.1093/med/9780197770337.003.0038 (opens in new tab)
Psilocybin
Anxiety
Depression economics
Cancer
+4